What Duran Treats: Main Uses and Benefits

Duran is relevant for easing symptomatic discomfort in various digestive health contexts where additional symptomatic support is needed. This class of medication is commonly used to help with conditions characterized by periods of heightened symptoms, such as those related to acid reflux and symptomatic ulcer manifestations.

Duran is applied in contexts marked by increased discomfort or tension, helping to address symptom clusters that may become intense or disruptive. The medication is relevant for easing symptoms linked to acid reflux, supporting symptomatic ulcer manifestations, and providing temporary relief for episodic discomfort (indigestion).

“It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.”

It is often used when symptoms intensify and supportive relief is needed, assisting with maintaining functional stability when symptoms are more noticeable.

Quick Fact: May Assist with Symptoms of Heartburn and Stomach Pain

Regulatory References

1. National Institutes of Health (NIH) MedlinePlus overview

Who Can and Cannot Use Duran? (Population Eligibility)

Use of Duran (Ranitidine) is governed by specific population eligibility rules documented by regulatory authorities. The information below reflects the medicine's official status for use, restriction, and non-eligibility.

---

Absolute Exclusion and Contraindications

Duran is contraindicated and must not be used by individuals with a documented hypersensitivity to Ranitidine Hydrochloride or any of the preparation's components. Use must be avoided in patients with a history of acute porphyria.

Prior to starting therapy for a suspected gastric ulcer, malignancy must be excluded as a mandatory precondition, as the medicine's effect can mask symptoms of gastric carcinoma.

Conditional Use and Restrictions

Eligibility requires specific medical considerations for certain populations:

• Organ Function: Patients with impaired renal function (Creatinine clearance below 50 mL/min) or hepatic dysfunction require conditional use and medical caution due to altered drug clearance.
• Age Groups: The medicine is approved for adults and pediatric patients from 1 month to 16 years of age. Conditional use is required for neonates (< 1 month) and older adults due to potential decreased kidney function.
• Reproductive Status: Use during pregnancy and lactation is restricted and should occur only if clearly needed or considered essential, as the drug crosses the placenta and is secreted into human milk.

Duran Interactions with other medicines and products

The interaction profile of Duran is structurally defined by its metabolism through the Cytochrome P450 3A4 (CYP3A4) enzyme and its status as a substrate for the P-glycoprotein (P-gp) transporter. This requires specific constraints when other substances are co-administered.

• Strong CYP3A4 Inducers (e.g., certain anticonvulsants, antitubercular drugs) are not recommended for co-administration. These drugs significantly decrease the concentration of Duran in the body, which can lead to a loss of the medication's intended effect.
• Strong CYP3A4 Inhibitors (e.g., specific azole antifungals, HIV protease inhibitors) can substantially increase Duran exposure. A mandatory dose reduction of Duran is required when these inhibitors are co-administered to manage this effect.
• Products that alter gastric pH (e.g., certain antacids or acid-reducing drugs) may decrease the absorption of Duran. Administration of Duran and these products must be separated by a specific time interval, as dictated in official prescribing information.
• Consumption of grapefruit or grapefruit juice is explicitly forbidden during treatment with Duran, as it significantly inhibits the enzyme responsible for Duran's breakdown, leading to elevated concentrations.

Patients on Duran who also take CYP3A4-sensitive drugs with a narrow therapeutic index require close clinical or laboratory monitoring, as Duran itself may alter the concentration of these co-administered medications.

How Duran Works

Duran works by precisely targeting key components of overactive signaling pathways to modulate pathway activity. Its mechanism involves a multi-domain approach, primarily focused on influencing specific receptors and enzymes that determine systemic signaling kinetics.

---

Modulating Receptor-Mediated Signaling

This domain addresses Duran's role in influencing receptor activity that is central to initiating or amplifying signaling sequences. Duran engages mechanisms that regulate these receptors, leading to a direct modification of early molecular steps and contributing to a reduction in signal amplitude within the affected neural or cellular network.

---

Regulating Enzyme-Driven Pathways

Duran engages specific mechanisms that regulate enzyme activity associated with the synthesis or degradation of key signaling mediators. By affecting systems where these transmitters dominate, Duran attenuates the effects of excessive mediator concentration, maintaining a modified homeostatic level within the targeted pathways and leading to altered downstream physiological parameter values.

Duran, which contains Ranitidine Hydrochloride, is administered via the oral route as tablets, effervescent forms, or syrup for routine use. It is also available for parenteral use via intravenous (IV) or intramuscular (IM) injection, typically reserved for hospitalized patients unable to tolerate oral administration. The overall usage pattern is defined by standardized dosing ranges and frequencies.

Regimen Type	Standard Adult Dose	Frequency
Acute Treatment	150 mg	Twice Daily (b.i.d.)
Maintenance	150 mg	Once Daily (at bedtime)
Parenteral	50 mg	Every 6 to 8 hours

Acute treatment courses for conditions like ulcers generally span four to eight weeks, while long-term maintenance regimens may continue for up to one year. The oral form’s absorption is not significantly affected by food, allowing for flexible timing; however, specific prophylactic use may require administration 30 to 60 minutes prior to a meal. Preparation of the oral form requires that effervescent tablets be fully dissolved in water before consumption.

Specific adjustments to the regimen are required for certain populations. Patients with severe renal impairment (creatinine clearance below 50 mL/min) must receive a reduced dose, typically 150 mg once daily. The dosing for pediatric patients is determined based on body weight. IV administration is a special procedural condition that must be conducted as a slow injection over at least five minutes.

Research Evidence / Overview of Studies

---

Mechanism of Action Studies

Research indicates the compound was studied to investigate its potential mechanism. Studies focused on how the compound interacts with cell processes. Studies examined whether this activity was observed alongside changes in disease progression. This approach is currently being investigated in studies for treating several types of solid tumors.

---

Clinical Trial Summaries

Studies explored the drug's activity in measuring endpoints related to disease status.

Advanced Melanoma

Studies have evaluated the compound's activity in treating advanced melanoma. Key research has explored how the combination with other therapies measured clinical endpoints. Available research reports on a tolerability profile observed in study populations.

Metastatic Breast Cancer

In research on metastatic breast cancer, the compound was studied to evaluate findings related to different assessment time points and longer-term observations. Research has typically investigated the compound's activity in the early stages of the disease.

Other Solid Tumors

This treatment has been the focus of recent research where its activity was examined alongside that of other established compounds. Data collected included information on observed side effects, and the compound was investigated for its activity related to immune system markers.

Key Studies & References

1. Clinical Trials Using Durvalumab - NCI - National Cancer Institute (General Scope and Indication Exploration)
2. Study on the Effects of Durvalumab, Oleclumab, and Chemotherapy in Patients with Luminal B Breast Cancer (Specific Breast Cancer Investigation)
3. Melanoma Clinical Trials - NCI - National Cancer Institute (Melanoma Research Context)

Common questions about Duran (FAQ)

---

Q: How long can I take Duran for?

The official product information indicates that the duration of treatment is based on the condition being addressed. For short-term issues, treatment courses typically run from four to eight weeks. If used for long-term management or maintenance therapy, official documents state that use may continue for up to one year.

---

Q: What is the risk of developing confusion with Duran?

Regulatory documents state that reversible mental confusion is a rare adverse effect that has been reported. This effect has been noted particularly in older adults and patients with impaired kidney or liver function. If it occurs, this confusion is generally noted to resolve once the medicine is stopped.

---

Q: How exactly does Duran work to change stomach acid levels?

Duran works by having its active ingredient, Ranitidine, act as an H2-receptor antagonist, often called an H2 blocker. This means it works by reversibly blocking H2 receptors found on the cells that line the stomach. This targeted action inhibits the signal that prompts the stomach to release acid, thereby reducing overall acid secretion.

---

Q: Which other drugs should not be taken with Duran due to CYP3A4 interaction?

Official labeling advises that caution or dose adjustment is necessary when Duran is taken with certain other medicines. This is especially true for strong CYP3A4 inducers (such as some drugs for seizures or tuberculosis) or strong CYP3A4 inhibitors (like certain antifungals or HIV medicines). Co-administration of medicines should be discussed with a healthcare professional, as these combinations can alter the concentration of Duran in the body.

---

Q: Can I drive or operate machinery while taking Duran?

Studies and official information indicate that Duran may cause side effects such as dizziness and, in rare cases, reversible mental confusion. If these central nervous system effects are experienced, caution is advised when driving or operating heavy machinery.

---

Q: Can I split the tablets in half to take a lower dose?

Unless the official instructions for a specific tablet formulation explicitly state that it can be split, oral tablets are typically intended to be swallowed whole. This ensures the intended dose is delivered as designed. Effervescent tablets, by contrast, must be fully dissolved in water before consumption.

---

Q: What should I do if I accidentally take too much Duran?

In the event that more Duran is taken than prescribed, official labeling indicates the need for prompt action. Contacting a healthcare professional for advice, or seeking immediate medical help, such as contacting a Poison Control Center, is indicated.

Official Storage and Handling Requirements

Duran (Ranitidine) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container, tightly closed, and protected from light and moisture. To maintain product quality, the desiccant must remain in the bottle. The medication must be kept out of the sight and reach of children.

Stability and Disposal Instructions

The official labeling mandates a stability limit: any unused tablets must be discarded after 90 days of first opening the bottle, or by the expiration date, whichever comes first. Disposal instructions prohibit discarding the medicine via wastewater or household waste. Instead, the product should be mixed with an unappealing substance, placed in a sealed bag, and disposed of in the trash, in accordance with applicable regulations.